InflaRx NV Share Price Today: Live Updates & Key Insights

InflaRx NV share price today is $0.9588, up 3.34%. The stock opened at $0.9576 against the previous close of $0.9096, with an intraday high of $0.9999 and low of $0.9217.

InflaRx NV Share Price Chart

InflaRx NV

us-stock
To Invest in {{usstockname}}
us-stock

InflaRx NV Share Price Performance

$0.9588 0.0334(3.34%) IFRX at 23 Mar 2026 01:37 PM Biotechnology
Lowest Today 0.9217
Highest Today 0.9999
Today’s Open 0.9576
Prev. Close 0.9096
52 Week High 1.94
52 Week Low 0.71
Day’s Range: Low 0.9217 High 0.9999
52-Week Range: Low 0.71 High 1.94
1 day return -
1 Week return +0.98
1 month return +9.55
3 month return -16.53
6 month return -30.64
1 year return -33.1
3 year return -51.63
5 year return -78.7
10 year return -

InflaRx NV Institutional Holdings

Suvretta Capital Management, LLC 11.71

683 Capital Management LLC 4.89

Bank of America Corp 3.65

Eversept Partners, LP 2.55

Ikarian Capital, LLC 1.07

Morgan Stanley - Brokerage Accounts 0.92

Two Sigma Investments LLC 0.60

Squarepoint Ops LLC 0.48

T3 Companies, LLC 0.43

Marshall Wace Asset Management Ltd 0.41

Jane Street Group LLC 0.27

DCF Advisers, LLC 0.23

Quadrature Capital Limited 0.15

Kestra Advisory Services, LLC 0.13

SIMPLEX TRADING, LLC 0.12

Lago Erie SICAV 0.11

Vifag 2002 SICAV 0.11

Citadel Advisors Llc 0.09

Insigneo Advisory Services LLC 0.09

Goyer & Göppel Smart Sel Universal 0.07

HRT FINANCIAL LLC 0.07

Fidelity Nasdaq Composite Index 0.06

Geode Capital Management, LLC 0.06

Susquehanna International Group, LLP 0.06

Azimut Trend 0.00

Azimut Trading 0.00

Azimut Strategic Trend 0.00

InflaRx NV Market Status

Strong Buy: 5

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

InflaRx NV Fundamentals

Market Cap 63.68 M

PB Ratio 1.2245

PE Ratio 0.0

Enterprise Value 13.12 M

Total Assets 55.19 M

Volume 1030350

InflaRx NV Company Financials

Annual Revenue FY23:60803 0.1M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-34763659 -34.8M, FY22:-27042313 -27.0M, FY21:-45654828 -45.7M, FY20:-34009614 -34.0M, FY19:-49741461 -49.7M

Quarterly Revenue Q3/2025:23830 0.0M, Q2/2025:39432 0.0M, Q1/2025:0 0.0M, Q3/2024:123819 0.1M, Q2/2024:6357 0.0M

Quarterly Profit Q3/2025:23497 0.0M, Q2/2025:-2360151 -2.4M, Q1/2025:-9291 -0.0M, Q3/2024:196374 0.2M, Q2/2024:-341796 -0.3M

Quarterly Net worth Q3/2025:-12261089 -12.3M, Q2/2025:-14416271 -14.4M, Q1/2025:-8314027 -8.3M, Q3/2024:-17449654 -17.4M, Q2/2024:-13845741 -13.8M

About InflaRx NV & investment objective

Company Information InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Organisation Biotechnology

Employees 74

Industry Biotechnology

CEO Prof. Niels C. Riedemann M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

InflaRx NV FAQs

What is the share price of InflaRx NV today?

The current share price of InflaRx NV is $0.9588.

Can I buy InflaRx NV shares in India?

Yes, Indian investors can buy InflaRx NV shares by opening an international trading and demat account with Motilal Oswal.

How to buy InflaRx NV shares in India?

You can easily invest in InflaRx NV shares from India by:

Can I buy fractional shares of InflaRx NV?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of InflaRx NV?

InflaRx NV has a market cap of $63.68 M.

In which sector does InflaRx NV belong?

InflaRx NV operates in the Biotechnology sector.

What documents are required to invest in InflaRx NV stocks?

To invest, you typically need:

What is the PE and PB ratio of InflaRx NV?

The PE ratio of InflaRx NV is N/A and the PB ratio is 1.22.